Product Summary

• Herceptin (Trastuzumab) biosimilar

• Bringing new high-quality option for clinical anti-HER2 Treatment

• The first commercial biologic of Bioray Oncology BU, got NMPA approval in 2023 Q1

• Funded by National Major Scientific and Technological Special Project for “Significant New Drugs Development"